INR102
/ Yunnan Baiyao
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 08, 2026
A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer
(clinicaltrials.gov)
- P1/2 | N=55 | Recruiting | Sponsor: Yunhe Pharmaceutical (Tianjin) Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1